Business Context and Reporting Period
This Form 6-K filing by BiondVax Pharmaceuticals Ltd. (not Scinai Immunotherapeutics Ltd.) covers the month of February 2018, with a specific report date of February 22, 2018. The registrant is a foreign private issuer based in Ness Ziona, Israel.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a corporate governance announcement and does not contain financial statements.
Material Changes
The primary material change reported is a corporate governance action: the Board of Directors approved the extension of Professor Avner Rotman's term as a director and chairman of the board.
Guidance, Outlook, and Management Commentary
The extension of Professor Rotman's term is for an interim period until the earlier of: (1) the election of a new chairman by the board, or (2) a period of one year from February 22, 2018. The filing contains no financial guidance, risk factors, or discussion of unusual items.
Investor Verification Checklist
- Verify the correct registrant name is BiondVax Pharmaceuticals Ltd., not Scinai Immunotherapeutics Ltd.
- Confirm the interim nature of Professor Avner Rotman's extended chairmanship.
- Note the absence of financial data in this specific filing.